A recent undercover investigation aired around the 3·15 consumer‑rights season has lifted the veil on a flourishing private‑domain marketing ecosystem that packages cheap medicines and supplements as miracle cures and sells them to older consumers through polished online lectures. Journalists attending an industry exchange in a central Chinese city found producers of so‑called “network video content” openly recruiting partners to supply scripted health talks, which are then played inside private social‑media channels to close sales.
The vendors at the heart of the operation buy commodity drugs and supplements at very low cost, sometimes reportedly for under 20 RMB a unit, then embed them in video courses delivered by people billed as “medical experts”, “association chairmen” or “students of traditional Chinese medicine”. These titles, industry insiders say, are little more than paid stage props. Products are marketed in private chat groups and livestreams at greatly inflated prices — in some cases advertised near 1,198 RMB — and promoted with exaggerated or altered claims about therapeutic benefit.
Reporting traced parts of this value chain to firms such as Shengwei Culture Media in the northeast and a company called “Dahong International”, whose managers openly warned journalists to “lay low until after 3·15”, the annual consumer rights gala hosted by state broadcasters that frequently triggers investigations and regulatory scrutiny. Several contracted instructors who record the courses declined in‑person meetings and advised postponing activity until the post‑3·15 period, reflecting acute awareness of legal and reputational risk.
The business model is systematic: video production companies buy inexpensive inventory from pharmaceutical or health‑product suppliers, create a package of lectures and testimonials, and sell the videos to private‑domain operators. Those operators then guide groups of consumers into restricted social‑media channels — the so‑called private domain — where curated content is used to stoke trust and urgency before closing high‑margin sales.
This is not merely an issue of sleazy advertising. The combination of counterfeit or misrepresented medical advice, seemingly authoritative spokespeople and a sales environment that isolates older consumers makes the practice particularly predatory. Seniors are a high‑value demographic for the industry: they are more likely to suffer chronic conditions, to trust medical authority, and to respond to guided peer pressure inside private chat groups.
The exposure raises immediate enforcement and platform‑governance questions. Chinese regulators have in recent years tightened rules on medical claims online and cracked down on performance marketing; the 3·15 spotlight tends to accelerate investigations and sanctions. Platforms that host private‑domain commerce — notably WeChat ecosystems, short‑video apps and independent CRM tools — face renewed pressure to police sellers, verify credential claims and cut payment flows to fraudulent operators.
For global observers, the episode is a reminder that digital health misinformation and commerce are not new problems confined to Western platforms. The specific contours reflect China’s social‑commerce ecosystem: private groups, closed‑loop payment and commercial relationships between small manufacturers, video producers and agented sales teams. Remedies will require coordinated enforcement, tougher platform accountability and better consumer education aimed at vulnerable groups.